Theriva Biologics Inc. Files Prospectus for Offering Up to $2.5 Million in Common Stock
Reuters
Jun 21
<a href="https://laohu8.com/S/TOVX">Theriva Biologics</a> Inc. Files Prospectus for Offering Up to $2.5 Million in Common Stock
Theriva Biologics Inc. has filed a prospectus supplement with the Securities and Exchange Commission, allowing for the offer and sale of up to $2,534,352 worth of its common stock. The sales will be conducted through A.G.P./Alliance Global Partners, acting as the sales agent in an "at the market offering." The prospectus is linked to Theriva's Registration Statement, which became effective on September 25, 2024. The sales agent will earn a commission of up to 3% on the gross sales price per share. The company has also agreed to provide indemnification and contribution for certain liabilities related to the offering. This filing does not constitute an offer to sell or solicitation to buy securities in any state where such actions would be unlawful.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061203), on June 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.